期刊文献+

葡膦酰胺静脉给药对比格犬的毒性作用

Toxicity of glufosfamide in Beagle dogs following intravenous injection
下载PDF
导出
摘要 目的:评价葡膦酰胺对比格犬的安全性。方法:观察葡膦酰胺单次静脉注射和连续静脉注射3个月对比格犬的毒性作用。结果:葡膦酰胺单次静脉注射比格犬最低致死剂量为100 mg/kg,最高非致死剂量为50 mg/kg,近似致死剂量范围为75~100 mg/kg。连续静脉注射20,40,60 mg/kg,每周1次,连续3个月,无严重不良反应症状,但组织病理学检查发现中、高剂量组出现广泛组织脏器损伤,低剂量组个别脏器出现轻微病理改变。结论:在本实验条件下,40,60 mg/kg剂量葡膦酰胺每周1次,连续3个月静脉给药可造成比格犬广泛的脏器损伤。每周1次,连续3个月静脉给药剂量应低于20mg/kg。 Aim:To evaluate the safety of glufosfamide in Beagle dogs.Methods:The safety of glufosfamide in Beagle dogs following single iv and multiple iv administration for 3 months was observed.Results:The minimum lethal dose of glufosfamide was 100 mg/kg.The maximum non-lethal dose of glufosfamide was 50 mg/kg.The approximate lethal dose of glufosfamide was 75-100 mg/kg.No serious adverse reactions was observed in Beagle dogs following multiple iv administration once a week for 3 months at the dose of 20 mg/kg,40 m...
出处 《中国药科大学学报》 CAS CSCD 北大核心 2009年第6期535-538,共4页 Journal of China Pharmaceutical University
关键词 葡膦酰胺 比格犬 毒性 glufosfamide Beagle dog toxicity
  • 相关文献

参考文献5

  • 1Ammons WS,,Wang JW,Yang Z,etal.A novel alkylating a-gent,glufosfamide,enhances the activity of gemcitabinein vitroandin vivo[].Neoplasia.2007
  • 2Briasoulis E,Judson I,Pavlidis N,et al.Phase I trial of 6-hourinfusion of glufosfamide,a new alkylating agent with potentiallyenhanced selectivity for tumors that overexpress transmembraneglucose transporters:a study of the European organization for re-search and treatment of cancer early clin[].Journal of Clinical Oncology.2006
  • 3Engel J,Klenner T,Niemeyer U,et al.Glufosfamide[].Drugs of the Future.2000
  • 4Ciuleanu TE,Pavlovsky AV,Bodoky G,et al.A randomisedphase III trial of glufosfamide compared with best supportive carein metastatic pancreatic adenocarcinoma previously treated withgemcitabine[].European Journal of Cancer.2009
  • 5G Giaccone,EF Smit,M Jonge,E Dansin,E Briasoulis,A Ardizzoni.Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group[].European Journal of Cancer.2004

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部